FDA accepts Organogenesis BLA for Amnuvx: what it means for Organogenesis stock

Published on 10/05/2026 at 05:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 58.00 percent to USD 42.80 million in the second quarter. For Organogenesis stock this means 2026 guidance of USD 179.00-215.00 million.

ORGO, US68621F1021, Illustration mit AI erstellt.

Organogenesis Holdings Inc. (US68621F1021) is facing a sharp operating reset after second-quarter 2026 net product revenue fell 58.00 percent to USD 42.80 million. On September 17, 2026, Ainvest reported that the FDA accepted the company's biologics license application for Amnuvx, a treatment candidate for symptomatic knee osteoarthritis. The agency set April 24, 2027 as the target action date.

FDA review meets a weaker quarter

The regulatory milestone gives Organogenesis a defined pipeline date, but the latest reported quarter shows the pressure on its established business. According to StockTitan, second-quarter net product revenue was USD 42.80 million, compared with USD 100.80 million a year earlier, while the net loss widened to USD 96.30 million.

The first half of 2026 produced net product revenue of USD 79.10 million versus USD 187.50 million in the prior-year period. Gross margin for the first half was 37.00 percent, making the recovery in wound care demand and reimbursement conditions central to the investment case.

Guidance sets a steep recovery hurdle

Organogenesis updated its 2026 total net revenue guidance to USD 179.00 million-USD 215.00 million, down from USD 564.20 million in 2025, according to StockTitan. The range implies a 62.00 percent to 68.00 percent decline, so the Amnuvx program is arriving while management is still managing a substantial revenue gap.

Cash, cash equivalents and restricted cash stood at USD 46.80 million on June 30, 2026, and the filing summary reported no outstanding debt obligations. That balance provides a financial reference point for the company as it funds commercial operations and advances its clinical pipeline.

Valuation remains tied to the pipeline

Organogenesis had a market capitalization of USD 171.1 million as of October 2, 2026. Its primary-exchange 52-week range was USD 1.32 to USD 7.08 on the same date, a wide span that reflects the market's sensitivity to regulatory and operating news.

ToAlpha lists November 5, 2026 as the next earnings date. That report should give investors a new test of whether the second-half revenue trajectory is moving toward the updated outlook.

Organogenesis market snapshot

Organogenesis had a USD 171.1 million market capitalization and a USD 1.32 to USD 7.08 52-week range as of October 2, 2026. The company develops regenerative medicine products for advanced wound care, surgical and sports medicine applications, while Amnuvx supplies the next major regulatory milestone in its pipeline.